Therapeutic options for sarcoidosis: new and old
- 1 September 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 8 (5) , 464-469
Abstract
The treatment of patients with sarcoidosis remains an important part of management. The role of corticosteroids has been questioned by some, while others have reported its value even in asymptomatic patients with interstitial lung disease. Cytotoxic agents have become standard therapy for some forms of chronic disease. Newer agents that modulate the immune response have been studied. A key cytokine in chronic sarcoidosis appears to be tumor necrosis factor. Drugs that inhibit its release or block its effect have been reported as effective for sarcoidosis.Keywords
This publication has 49 references indexed in Scilit:
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- A role for methotrexate in the management of non-infectious orbital inflammatory diseaseBritish Journal of Ophthalmology, 2001
- Discrepancy between Inducibility of Ventricular Tachycardia and Activity of Cardiac Sarcoidosis. Requirement of Defibrillator Implantation for the Inactive Stage of Cardiac Sarcoidosis.Internal Medicine, 2001
- Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosisThe Lancet, 1999
- Methotrexate treatment for sarcoid-associated panuveitisOphthalmology, 1999
- Hydroxychloroquine and visual screening in a rheumatology outpatient clinicAnnals of the Rheumatic Diseases, 1997
- British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.Thorax, 1996
- Treatment of cutaneous and pulmonary sarcoidosis with thalidomideJournal of the American Academy of Dermatology, 1995
- Chloroquine in the treatment of sarcoidosisTubercle, 1967
- Ghloroquine Therapy in 43 Patients with Intrathoracic and Cutaneous SarcoidosisActa Medica Scandinavica, 1964